Washington – October 02, 2026 -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is presenting three new data sets on its monoclonal antibody imsidolimab at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Vienna, Austria, running September 30 through October 3, 2026.
Vanda shows imsidolimab cuts neutrophil levels rapidly in GPP patients
Poster P1769 (Abstract AS-4323) reports a rapid reduction in neutrophils and the neutrophil percentage-to-albumin ratio following imsidolimab treatment in patients with generalized pustular psoriasis (GPP), a rare orphan skin condition.
Immunogenicity data on imsidolimab presented in separate poster
A second poster, P1784 (Abstract AS-2420), details the immunogenicity profile of imsidolimab in GPP patients.
GEMINI-1 study results show pustulation improvement under Pustulation Rating Scale
Poster P2806 (Abstract AS-2421) presents results from the GEMINI-1 study showing imsidolimab improved GPP pustulation as measured by the Pustulation Rating Scale (PRS).
Vanda holds exclusive global license covering therapy into late 2030s
Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling. Vanda holds an exclusive global license for its development and commercialization, with the company expecting regulatory and patent exclusivity for the drug to extend into the late 2030s.